Two-source page, confidence: low. The body below is SACN 2015; (Nordic Council of Ministers, 2023) was added 2026-07-28 and is the second guidance family this page AWAITS-ed.
It does not raise confidence, and the section at the bottom explains why: NNR read SACN. The
questions this page answers are ones the maintainer holds a stated prior on (SC-11) — a reason for
more scrutiny of agreement, not less.
Reynolds 2019 is now held and woven (the fibre-benefit section below; ingested 2026-07-30) — but
note Reynolds shares an author with Te Morenga, so it cannot corroborate independently, and NNR
leans on Reynolds for its whole-grain dose-response, so that dependency runs through this page too. The
convergence it appears to add is therefore shared-source, not type-E.
The headline: refined grains are NOT found harmful
| Exposure -> outcome | Estimate | SACN grade |
|---|---|---|
| Refined grains -> cardiovascular events | RR 1.00 (95% CI 0.98, 1.01) per half serving/day, p=0.5 | No association · Moderate |
| Refined grains -> type 2 diabetes | RR 1.00 (95% CI 0.98, 1.01), p=0.7 | No association · Moderate |
(Scientific Advisory Committee on Nutrition, 2015)
And the randomised comparisons are null across the board. SACN states the comparator explicitly —
«All trials compared whole grain diets to refined grain control diets.» — then reports no effect on
systolic BP (0.2 mmHg, 95% CI -1.6 to 2.0; p=0.85), diastolic, total cholesterol (0.04 mmol/L,
95% CI -0.12 to 0.20; p=0.49), triacylglycerol, fasting glucose (-0.05 mmol/L, 95% CI -0.12 to 0.02;
p=0.14), fasting insulin and insulin sensitivity — several at Adequate evidence.
(Scientific Advisory Committee on Nutrition, 2015)
The one non-null randomised outcome favours whole grains, on an intermediate:
«An effect is demonstrated for higher whole grains consumption on reducing energy intake (-360 kJ,
95% CI -642, -79; p=0.01)» — graded Effect · Limited evidence, and SACN notes one trial
contributes 75% of the pooled estimate.
(Scientific Advisory Committee on Nutrition, 2015)
The claim that survives is narrower than the popular one
Whole-grain benefit is cohort-only and mostly Limited — CVD RR 0.95, stroke RR 0.96, colo-rectal
RR 0.97, the last graded No association. And SACN attaches its own attribution caveat:
«Any associations indicated for whole grain may be related to its cereal fibre component.» (Scientific Advisory Committee on Nutrition, 2015)
So the supported claim is whole grains are associated with lower risk in cohorts, possibly via fibre — NOT refined grain causes harm. Those are different claims and SACN separates them.
Decision consequence. Replacing refined with whole grain is supported as a plausible small
benefit routed through fibre, on cohort evidence. Avoiding refined grain as a harm-avoidance move
is not supported by this source — the harm estimate is a flat null at Moderate, SACN’s middle
strength grade.
Self-critique correction (2026-07-27): the first draft called
Moderate“the strongest evidence-state SACN issues for a no-association verdict.” False — SACN does issueNo association · Adequateelsewhere[searched: "no association"+"adequate", both orders, across all 13 SACN chunks]. So the refined-grain null sits one grade below SACN’s ceiling, not at it. The conclusion is unchanged; its stated strength was inflated.-> [[Is the Food Category Doing Any Work]]— “grain” may be the wrong unit; the fibre caveat says so in SACN’s own voice.
Challenge — “surely refined grains cause diabetes/obesity?” — disaggregate the exposure (2026-08-01)
A common, reasonable doubt (deliverable-critique). The RR 1.00 is a population main-effect, incidence estimate and it stands — but the harm intuition survives in three disaggregated forms the flat null does not touch, and conflating them with “refined grains” is what makes the null feel wrong:
- Refined grains =/= free sugars / SSBs. The evidenced carbohydrate harm on adiposity is free sugars, above all sugar-sweetened beverages -> Free Sugars Intake — a different exposure from the starchy refined-grain category tested here. The “refined carbs are bad” prior borrows most of its force from the sugar evidence.
- Incidence (null here) is not glycaemic control in the already-impaired. In established T2D / insulin resistance, reducing carbohydrate / glycaemic load improves glycaemic control and can drive remission -> Carbohydrate Restriction and Type 2 Diabetes Remission. That is a route-(b/c) management finding in a stratum; it does not contradict a null on refined-grain -> T2D incidence in the general population, and the general null does not close the stratum question.
- The null is substitution- and measurement-error-attenuated. RR 1.00 is “per half serving/day” with the replacement unspecified, and self-reported grain intake carries large error that biases a real gradient toward the null -> Measurement Error in Dietary Assessment. Read it as “no main-effect harm detected,” not “refined grain proven inert.”
Net: the population null is sound; the decision-relevant residue is (i) cut free sugars/SSBs, and (ii) cut glycaemic load if you are insulin-resistant — neither of which is “avoid refined grain as a food category.”
Is “fibre content” the whole target? Added fibre =/= intrinsic whole-grain fibre (2026-08-01)
SACN attributes the whole-grain signal to its cereal-fibre component, so fibre content is a better target than the word “whole grain” — this much is directionally right. But it is necessary, not shown sufficient, and it does NOT license “refined grain + added isolated fibre = whole grain” (deliverable-critique). Two held reasons: the isolate-vs-food caveat — isolated fibre is proven only on the LDL surrogate, not on the cohort mortality endpoint -> Dietary Fibre and Health; and the intact-grain matrix — cell-wall structure, particle size and fibre type/fermentability plausibly do work a milled grain plus a fibre additive does not -> Is the Food Category Doing Any Work. So the equivalence of fortified/added fibre to intrinsic whole-grain fibre on hard outcomes is not established — an open question, not a demonstrated sameness; “target fibre” ranks fibre above the label, it does not flatten the matrix.
Pulses — SACN largely did not look, and that is the finding
Where measured, null: legume fibre -> T2DM RR 1.01 (0.98, 1.04) per 1 g/day; legume fibre -> colo-rectal cancer RR 0.98 (0.94, 1.02); non-soy legume -> CVD RR 0.96 (0.90, 1.03). The one positive is faecal weight, which SACN itself bounds:
«The biological relevance is unclear due to the size of supplements, and it is unclear whether this finding is applicable to all legume fibres.» (Scientific Advisory Committee on Nutrition, 2015)
Two reasons those nulls are weak evidence of absence, not evidence of no effect.
- Roughly fourteen legume outcome cells sit in the
insufficient evidencetables against that single conclusion. Silence here is un-studied, not un-associated — the expectancy test applies. - The nulls are low-power by construction. SACN standardises increments to ~1 SD of UK intake, and legume fibre’s SD is 1 g/day against 7 g/day for total fibre. A null estimated across a distribution one-seventh as wide, in a low-consumption population, is close to uninformative about what happens at high intake. (inferred from Scientific Advisory Committee on Nutrition, 2015)
Pulses appear in exactly one SACN recommendation, and it is about weaning — “from about six months of age gradual diversification of the diet to provide increasing amounts of whole grains, pulses, fruits and vegetables is encouraged.”
This is a G gap, stated as one: the wiki cannot currently answer whether pulses help, harm, or
do nothing at the intakes someone considering them would actually eat. -> SC-11
Update [2026-08-28]: this gap is now partly addressed by a dedicated legume SR+MA
(Thorisdottir 2023, NNR2023) — cohort-null on hard CVD/T2D events across a low intake range, benefit
on LDL-C at RCT doses, «limited – no conclusion» overall. See The pulses G gap gets its dedicated
SR+MA below.
Update [2026-09-09]: the MORTALITY cell — the one Thorisdottir left open (it covered events +
risk factors, not death) — now has a number from a dedicated legume->mortality dose-response MA
(Zargarzadeh 2023): non-soy legumes -> ~6% lower all-cause mortality per 50 g/d (moderate certainty),
but no robust signal on any specific cause of death. See The pulses mortality cell gets its number
below.
What this page does NOT establish
-
Nothing about preparation — now held on a sibling page. Soaking, cooking, fermenting and germinating are untouched by SACN;
Petroski - Antinutrients Narrative Review 2020was ingested 2026-07-29 and addresses them directly -> Antinutrients in Plant Foods (preparation defuses the antinutrient concern for prepared plant staples; raw high-lectin legumes are the exception that requires a full boil). -
Nothing about carbohydrate load or bulk tolerance — partly held on a sibling page. SACN excluded gastrointestinal tolerance from its remit. The related protein question — that hitting a protein target from plants costs more food mass because plant DIAAS is low (peas 64, wheat 40 vs (Food and Agriculture Organization of the United Nations, 2013) milk 122) — is now held at Protein Quality and the DIAAS Score; the exact carb/bulk arithmetic remains a
Ggap (needs a food-composition dataset). -
Nothing about ultra-processing. “Refined” here is a grain-milling property, not a processing classification;
Hall - Ultra-Processed Diets Inpatient RCT 2019is the staged source for that and is a different question.
Self-critique [run 2026-07-27, before commit]
- Over-claim: FOUND and fixed.
Moderatewas described as SACN’s strongest no-association grade; it is not —No association · Adequateoccurs in the report. Corrected in place with the search scope recorded. This error inflated a finding that runs AGAINST the maintainer’s stated prior (SC-11, bias against processed grains), so it is not flattery — it is the ordinary one-notch-too-strong failure, and it appeared even on a claim there was no motive to strengthen. - Absence claims: three appear in What this page does NOT establish (preparation, tolerance, ultra-processing). The tolerance one is sourced — SACN states the exclusion. The other two are scoped to this source, not to the literature. Held.
- Laundered independence: none claimed. The page flags in advance that Reynolds shares an author with Te Morenga and cannot corroborate independently. Clean.
- Residual risk: single-source,
confidence: low, and the pulses section leans on an power argument that is the wiki’s, not SACN’s. Marked as such.
Fibre ISOLATES are better evidenced than fibre-bearing foods — and SACN bounds why [chunk 09]
This cuts against the usual intuition that whole food beats supplement, and SACN’s own grades say so:
«• Effect • Adequate evidence • The direction of the effect demonstrates higher consumption of fibre isolates and gum supplements is beneficial to health • The effect is biologically relevant, but demonstrated at intakes achieved through supplementation» (Scientific Advisory Committee on Nutrition, 2015)
«• Effect • Moderate evidence • The direction of the effect demonstrates consumption of cellulose is potentially beneficial to health • The effect is potentially biologically relevant, but demonstrated at concentration of intake achieved through supplementation» (Scientific Advisory Committee on Nutrition, 2015)
| Form | SACN’s strongest grade for it | Design |
|---|---|---|
| Fibre isolates + gum supplements | Effect · Adequate — SACN’s top strength grade | supplement trials |
| Cellulose | Effect · Moderate | supplement trials |
| Psyllium | Effect · Moderate and Effect · Limited — the grade varies by outcome | supplement trials |
| Whole grains | mostly Limited; colo-rectal graded No association | cohort only |
The asymmetry is a DESIGN artifact, not a verdict on food versus supplement. Isolates can be
randomised at a chosen dose; whole-grain intake mostly cannot, so it is observed. The better grade
tracks the better design, not the better food — and SACN attaches the transportability caveat
itself, twice, in the same clause as the finding: the effect is demonstrated at supplement-level
intakes, which is not a claim about eating more of a fibre-bearing food.
(inferred from Scientific Advisory Committee on Nutrition, 2015)
-> [[Is the Food Category Doing Any Work]], -> [[Upgrading Observational Evidence]]
The 30 g target against what people actually eat [chunk 08/10]
«Setting the dietary reference value for AOAC fibre at 30g/day for adults means that current mean intakes would be 10-11g below the dietary reference value for men and 13g below for women.» (Scientific Advisory Committee on Nutrition, 2015)
A ~40% shortfall against the target, population-wide. Two consequences:
- A “get to 30 g” recommendation is a large behaviour change, not a tweak — and the telos requires judging interventions on adherence, not on the ideal.
- The evidence for benefit is strongest in the range people are already leaving, which is where the dose-response is estimated -> Measurement Error in Dietary Assessment.
Do not compare this figure to the NSP tables. SACN’s annex reports non-starch polysaccharide intakes of ~11-15 g/day by age and sex (Table 3.12) — NSP is a narrower measure than AOAC fibre and the two are not interchangeable. SACN’s own AOAC-terms statement above is the comparison to use; reading the NSP number against the 30 g AOAC target would overstate the shortfall.
Self-critique of the chunk-09/10 additions [run 2026-07-27, before commit]
- Grade error: FOUND and fixed. The isolate table listed psyllium as
Effect · Limitedonly. SACN issues psyllium conclusions at bothModerateandLimited, varying by outcome[searched: "(adequate|moderate|limited) evidence ... psyllium" across chunk 09]. Corrected. A single grade per substance is the wrong shape — SACN grades exposure-outcome pairs, so any table keyed on substance alone will misrepresent it. - Same-quantity error: AVOIDED, and recorded as a near miss. The NSP intake figure (~11-15 g/day) was about to be compared against the 30 g AOAC reference value. They are different measures. SACN supplies the correct AOAC-terms comparison itself; the near miss is documented on Measurement Error in Dietary Assessment rather than quietly dropped.
- Over-claim check on the isolate asymmetry. The claim that better grades track better design rather than better food is tagged — SACN states the supplementation bound but does not draw the design contrast. Held, and correctly attributed to the wiki.
- Adjudication check (the new rule): no
SC-NNrow was scored and no challenge adjudicated in this pass. The fibre-isolate material bears onSC-07andSC-18; the handles are noted in the log line only, and the scoring is left to a separate operation. - Residual: still a single-source page at
confidence: low. The isolate-vs-food asymmetry is the kind of finding a second source could easily overturn.
The second guidance family arrives — and it is not a second witness [2026-07-28]
NNR cashes the AWAITS above. The first thing it
establishes is that it cannot corroborate this page, and NNR says so itself by listing its inputs:
«Seven qSRs are available on the role of cereals (grains) and health outcomes (Fogelholm et al., > 2012; Hauner et al., 2012; Reynolds et al., 2019; SACN, 2015; WCRF/AICR, 2018b, j; Åkesson et al., > 2013).» (Nordic Council of Ministers, 2023)
SACN 2015 is one of the seven. So NNR agreeing with SACN on grains is a body agreeing with a
review it read — not independent backing, and no [E-independent] is claimable. The surface
markers again point the wrong way (different country, different decade, different committee,
convergent conclusion), which is exactly the trap the laundering guard exists to catch.
Refined grains: the two bodies describe the evidence base differently
Parameter table (op-weave 2a):
| Parameter | SACN 2015 | NNR 2023 | Same quantity? |
|---|---|---|---|
| Exposure | «refined grains», per half serving/day | «refined grains (flour) specifically» | NO — NNR’s parenthetical narrows to flour |
| Outcome | cardiovascular events; type 2 diabetes | health outcomes, unspecified in the adverse-effects box | NO — SACN names outcomes, NNR does not |
| Estimate | RR 1.00 (0.98, 1.01), both outcomes | none given | NO — one is a pooled estimate, the other a statement about literature volume |
| Evidence-state verdict | No association · Moderate | «Few or no studies on refined grains (flour) specifically» | NO — measured-null vs unstudied |
| Benefit claim | not asserted | «available evidence does not indicate similar beneficial associations compared with whole grains» | comparable in direction only |
The fourth column is NO on every substantive row, so the honest artifact is a distinction, not a tension — and the distinction is one the telos names explicitly.
SACN and NNR occupy two of the four evidence states, on what looks like one question. SACN pooled
cohort data to a flat null and graded it Moderate — no meaningful effect. NNR reports «Few or no
studies on refined grains (flour) specifically» and lists the sparsity in its data-gaps block —
insufficient evidence. These are not the same verdict, and the telos is explicit that they must
not be collapsed.
Before reading that as a contradiction, note what dissolves most of it. The exposures are not the same: SACN estimated refined grains as a food category from cohorts; NNR’s sparsity claim is scoped by its own parenthetical to flour specifically. A category can be well-estimated in aggregate while its individual constituents are not — which is Is the Food Category Doing Any Work running in the opposite direction to its usual use. What survives is narrower and still useful: two Tier-A bodies looking at overlapping literature reached “measured and null” and “barely studied”, and a reader told only one of the two would form a different picture of how settled this is.
What NNR adds that SACN does not have
-
An explicit carve-out for refined grains, on an energy-adequacy warrant. NNR’s science advice based on health outcomes ends: «At high energy requirements refined grains also have a role. This justifies allowing some refined cereals in the diet.» SACN issues no equivalent — it reports a null and stops. This is a decision-change for one identifiable stratum (high energy requirement: athletes, heavy manual work, high-growth adolescence), and it converts a null into a permission. (Nordic Council of Ministers, 2023)
-
A quantified whole-grain target with a stated direction beyond it: «It is recommended to consume at least 90 g/day (dry weight) of whole grains (including whole grains in products), with likely further benefits of higher intakes. Such further intakes have no adverse effects». Compare the units before comparing the numbers — NNR’s 90 g/day is dry weight of whole grains; SACN’s 30 g/day is AOAC fibre. Different substances, different measures, not comparable, and the page’s existing NSP-vs-AOAC warning applies with more force here. (Nordic Council of Ministers, 2023)
-
A dose-response statement that may or may not describe a knee — recorded as.
«Dose-response curves show that risk reduction for all-cause mortality is observed for intakes up to 50-60 g/day of whole grains. Higher intakes (i.e. 90 g/day) confer even greater risk reduction for coronary heart disease, type 2 diabetes and colorectal and breast cancer (Reynolds et al., > 2019).» (Nordic Council of Ministers, 2023)
«observed for intakes up to 50-60 g/day» read two ways — and Reynolds 2019 (now held) settles it as the data edge, not a knee. NNR attributes the sentence to Reynolds, and Reynolds’ own dose-response is explicit: «Figure 1 shows dose-response relationships … many of which are linear with no sign of a plateau within the available data», with whole-grain benefit still climbing to 90 g/day for CHD, T2D and cancer. So the «up to 50-60 g/day» marks how far the all-cause data extend, not a flattening — there is no outcome-specific knee here. This is the SACN pattern again (a number marking the edge of the evidence, not a feature of the curve), and it is consistent with, not a counter-instance to, the dose-response prior. (Reynolds et al., 2019)
Self-critique of the NNR addition [run 2026-07-28, before commit]
- Fake-tension check: FIRED, and the tension was NOT filed. The attractive claim here was “two Tier-A bodies contradict each other on refined grains.” The parameter table returned NO on four of five rows — different exposure scope (flour vs category), different outcomes, estimate vs literature-volume statement. Filed as a distinction with the residual stated. This is the finding the guard was built for, and it would have read very well as a tension.
- Laundered independence: checked and denied, from NNR’s own text. NNR lists SACN 2015 among its seven cereal qSRs. Stated up front rather than buried, and the page header was rewritten so a reader does not take “two sources” as “two witnesses”.
- Over-claim check on the carve-out. «At high energy requirements refined grains also have a role» is quoted, not paraphrased, and the stratum named (athletes, manual work, adolescence) is the wiki’s illustration of “high energy requirements”, not NNR’s list. Flagged here rather than in the body.
- Same-quantity near miss: AVOIDED. NNR’s 90 g/day whole grains was about to sit near SACN’s 30 g/day fibre target. Dry weight of a food against an AOAC fibre measure — recorded in the body as a non-comparison.
- Dose-response: declined to score. The sentence is the only candidate knee in the corpus and the temptation was to bank it against the falsified prior. Left open, source named.
- Residual:
confidencestayslowand the source count going from one to two changes nothing epistemically, which is the whole point of the section.
The pulses gap gets a first number — from a third guidance family [2026-07-28, ESC]
This page files pulses as a G gap, stated as one: the wiki could not say whether pulses help,
harm or do nothing at realistic intakes. ESC supplies the first
quantified claim the corpus holds.
«A single portion of pulses (legumes) a day low- ers LDL-C by 0.2 mmol/L and is associated with a lower risk of CHD.» (European Society of Cardiology, 2021)
Read the sentence’s two halves separately — they are different evidence classes, and ESC runs them together:
| Claim | Outcome type | Evidence form as stated |
|---|---|---|
| LDL-C -0.2 mmol/L per daily portion | surrogate | a magnitude, so presumably trial-derived |
| «associated with a lower risk of CHD» | hard outcome | associational, no magnitude, no interval |
Only the surrogate limb carries a number. So the gap narrows rather than closes: the wiki can now say one portion a day moves LDL-C by a stated amount, and still cannot say what pulses do to events at that intake. -> Surrogate Outcomes
How this sits against SACN, which is the page’s incumbent. SACN found legume-fibre nulls (T2DM RR 1.01; colo-rectal RR 0.98) and this page already explains why they are weak evidence of absence — the increment was 1 g/day against 7 g/day for total fibre, a low-power slice. ESC’s exposure is a whole portion of the food, not a 1 g fibre increment, so the two are not the same quantity and ESC does not contradict SACN. The honest composite: a null across a narrow fibre slice, and a surrogate benefit at a food-level dose. Both can hold.
No [E-independent], and no sources: inflation of the claim’s strength — ESC gives one sentence
with two references and no certainty rating, in a guideline whose subject is cardiovascular prevention
rather than pulses.
Fibre: a fourth family, and the first one to give a RANGE [2026-07-28, ESC]
ESC’s Table 8 specifies «3045 g of fibre of per day, preferably from wholegrains» (i.e. 30-45 g; the hyphen is lost in the source’s OCR). (European Society of Cardiology, 2021)
| Body | Fibre target | Form | Method specified? |
|---|---|---|---|
| SACN | 30 g/day | point | yes — AOAC |
| WHO | >=25 g/day | floor | not held |
| NNR | 3 g/MJ primary; 25 g/d female, 35 g/d male | energy-scaled + sex-split | no |
| ESC | 30-45 g/day | range | no |
Four bodies, four constructs — and the wiki cannot rank them. A point, a floor, an energy-scaled value and a range are not four estimates of one quantity; and only SACN names the analytical method, which this page already records as the thing that makes 30 g and 25 g non-comparable. ESC’s upper bound of 45 g is the highest figure in the corpus and comes with no stated warrant, so it is recorded as a held position, not as evidence that more is better.
The whole-grain benefit is probably the FIBRE benefit [2026-07-29, Reynolds]
Reynolds 2019 (the WHO-commissioned Lancet meta-analysis) tracks whole grains and total fibre in the same study, and the parallel is close: higher whole-grain intake tracks a 13-33% risk reduction across critical outcomes (per 15 g/day, all-cause mortality RR 0.94, 0.92-0.95), while total fibre tracks 15-30% (per 8 g/day, all-cause 0.93). Reynolds grades fibre moderate but whole grains only low-to-moderate, and notes the gap «could reflect the high fibre content of whole grains» — i.e. whole grains likely act through their fibre rather than as a separate lever. This is the component-not-category reading on this page, now with a magnitude on both sides -> Dietary Fibre and Health. It also sharpens the target: if fibre is the active fraction, fibre content (not the word “whole grain”) is what to steer by. (Reynolds et al., 2019)
Low whole grains tops the GLOBAL burden ranking — but read that as prevalence, not effect size [2026-08-04, Afshin GBD 2017]
GBD 2017 ranks low whole-grain intake the #1 dietary risk factor for DALYs globally (82 million DALYs, ~3 million deaths; leading risk in 16-17 of 21 world regions) — the foundational source behind the NNR ranking on Layer 1 - Ranking Interventions for a Stratum. (Afshin et al., 2019)
This does NOT upgrade the effect this page holds, and conflating them is the trap. The whole-grain
benefit here is cohort-only, low-to-moderate certainty, and probably the fibre benefit routed
through a food label. GBD’s #1 rank is attributable burden = that same modest observational RR x the
near-universal shortfall (global mean intake is only 23% of optimal). A common exposure with a small
individual effect tops a population ranking; the rank is a fact about how widespread low intake is,
not about how large the per-person gain is -> the prevalence-wedge distinction on the Layer-1 page. So
the page’s confidence: low on the effect stands unchanged; GBD adds a population-priority signal, not
an effect-size upgrade. (inferred from Afshin et al., 2019)
A fifth family — a cancer body grades whole grains, and it lands on colorectal [2026-08-05, WCRF]
WCRF’s Third Expert Report is the first cancer-prevention family on this page, and its grade is site-specific: «Consuming wholegrains helps protect against colorectal cancer» — a probable (strong-enough-to-recommend) protective judgement — with dietary fibre graded the same way, and pulses (legumes) folded into the recommended plant-food pattern. (World Cancer Research Fund & American Institute for Cancer Research, 2018) Its fibre goal — «at least 30 grams per day … from food sources» — is the same ~30 g target the guidance families above already converge on, now reached from a cancer endpoint rather than CHD/T2D.
Two things it corroborates, neither an independent witness. (i) On refined grains WCRF draws no
harm conclusion (matrix «limited – no conclusion»), consistent with this page’s headline that refined
grains are not found harmful. (ii) Its wholegrain->colorectal judgement rests on the CUP cohort SLRs
that overlap Reynolds’ colorectal-cancer cohorts — shared observational base, so this is F/shared,
not [E-independent] (and WCRF adds no sources: strength beyond the extracted grade).
(Reynolds et al., 2019; inferred from World Cancer Research Fund & American Institute for Cancer Research, 2018)
The cancer grade’s softness is documented on Dietary Fibre and Health (Veronese’s weak colorectal-
fibre signal + adenoma RCT-null); the whole-grain benefit here stays confidence: low, cohort-only.
Appraising this observational evidence — the instrument [2026-07-31]
The whole-grain benefit is cohort-only; ROBINS-I (Risk of Bias Assessment Tools) is the appraisal tool, with domain 1 (confounding) and domain 3 (classification — what counts as “whole grain”) the likely caps. Re-appraisal candidate on the RoB-tools page; not re-graded here.
A sixth family adds GI/GL as a co-equal carb-quality marker — Jenkins 2024 [2026-08-13]
Jenkins 2024 (gold MA, 10 mega-cohorts) compared low-GI diets directly against high-whole-grain diets in the same cohorts and found «Associations between diets high in fibre and whole grains and the four main outcomes were similar to those for low GI diets». (Jenkins et al., 2024) Most GI-vs-wholegrain group-difference p-values were non-significant — but the comparison «only included one or two cohorts for most outcomes», so the equivalence is thinly powered. This strengthens this page’s component-not- category reading: whole grain, fibre and GI/GL are collinear markers of one carbohydrate-quality pattern (the source itself notes «foods high in carbohydrates also tend to have a high GI»), so their near-identical associations do not establish any one as an independent lever. Full GI/GL magnitudes and the proxy-vs-lever analysis: Glycaemic Index and Glycaemic Load and Chronic Disease. (inferred from Jenkins et al., 2024)
The bare whole-grain RRs get a dose-response, CIs and a studied range — Aune 2016 [2026-08-13]
The whole-grain figures above (SACN’s cohort RR 0.95 CVD / 0.96 stroke / 0.97 colo-rectal, no CI, no shape; NNR’s bare 90 g/day) were the page’s weakest presentation: a bare point estimate carries no decision. Aune 2016 (gold dose-response MA, 45 prospective cohorts / 64 publications, up to 705 253 participants, 100 726 all-cause deaths) supplies the per-90 g/day RR + 95% CI + curve shape + studied range the page lacked — a type-F refinement of the incumbent bare figures, not a new route to the claim.
| Outcome (per 90 g/day = 3 servings) | RR (95% CI) | I2 | n | |
|---|---|---|---|---|
| Coronary heart disease | 0.81 (0.75-0.87) | 9% | 7 | sig |
| Cardiovascular disease | 0.78 (0.73-0.85) | 40% | 10 | sig |
| All-cause mortality | 0.83 (0.77-0.90) | 83% | 11 | sig; high I2 |
| Total cancer mortality | 0.85 (0.80-0.91) | 37% | 6 | sig |
| Stroke | 0.88 (0.75-1.03) | 56% | 6 | NS |
| Respiratory mortality | 0.78 (0.70-0.87) | 0% | 4 | sig |
«The summary relative risks per 90 g/day increase in whole grain intake … was 0.81 (95% confidence interval 0.75 to 0.87; I2=9%, n=7 studies) for coronary heart disease, 0.88 (0.75 to 1.03; I2=56%, n=6) for stroke, and 0.78 (0.73 to 0.85; I2=40%, n=10) for cardiovascular disease» (Aune et al., 2016)
90 g/day is a population median, NOT an optimum — benefit keeps climbing to ~7 servings/day.
«Reductions in risk were observed up to an intake of 210-225 g/day (seven to seven and a half servings per day) for most of the outcomes.» (Aune et al., 2016)
All-cause risk is lowest at 225 g/day; the curves are steeper at low intake then flatten (concave) but stay decreasing to the studied-range edge — no plateau reached within the data, no upper (harm) arm for the headline outcomes. So NNR’s 90 g/day threshold marks study density / a median, not a ceiling — the SACN pattern again (a guideline number marking the evidence edge, not a curve feature), consistent with the falsified knees-prior. No U-artifact: the lone point estimate above 1 is nervous-system mortality (1.15, 0.66-2.02, n=2, NS) at low intake only — a weak single outcome, not a U on the headline curves -> The U-Shaped Association Artifact.
Unit caveat — Aune’s 90 g =/= NNR’s 90 g. Aune’s increment is mostly fresh weight (product including water: only 2 of the pooled publications used dry weight), whereas NNR’s 90 g/day is dry weight. The numeric coincidence hides a fresh-vs-dry difference; do not read the two 90 g figures as the same dose. (Aune et al., 2016)
Refined grains — Aune corroborates the page’s headline null (F/shared). Per 90 g/day: CHD 1.13 (0.90-1.42, NS), stroke 0.91 (0.81-1.02, NS), CVD 0.98 (0.90-1.06, NS), all-cause 0.95 (0.91-0.99, weak inverse). Aune’s own summary: «there was little evidence of an association with refined grains, white rice, total rice, or total grains.» (Aune et al., 2016) Neither benefit nor a measured HARM signal — so the refined-grain carve-out in guidance is compositional (whole grain carries more of the active fraction), not a demonstrated harm of refined grain, exactly as SACN’s RR 1.00 and WCRF’s «no conclusion» already established. This corroborates, it does not independently witness (see below).
No [E-independent] — DENIED on shared-cohort grounds. Staging notes hypothesised Aune is a genuine
type-E witness vs Reynolds because the teams are independent (Imperial/Aune vs Otago/Reynolds-Te
Morenga). Verified and downgraded to F/shared on ingest: both are cohort-pooling meta-analyses
drawing on a substantially overlapping primary cohort base (Wu 2015 NHS/HPFS, Johnsen 2015 HELGA,
Jacobs Iowa, ARIC, EPIC, PREDIMED). Same method + same primary data = shared-source agreement, not two
independent routes — the strict-E rule (re-pooling the same studies is laundered-E), exactly like the
NNR-reads-SACN and WCRF-shares-Reynolds’-cohorts denials already on this page. Team-independence is not
evidence-independence. Confidence stays low: Aune sharpens the precision and shape of the estimate,
it adds no independent backing.
(inferred from Aune et al., 2016; Reynolds et al., 2019)
Full extraction, all outcome cells and the observational caveats: Aune 2016 source page (Aune et al., 2016).
Self-critique of the Aune addition [run 2026-08-13, before commit]
- Laundered-independence check: FIRED, and
[E-independent]was NOT claimed. The attractive claim was an independent Imperial team confirms Reynolds’ whole-grain->mortality signal. Both are cohort-pooling MAs on a substantially overlapping primary base (Wu/NHS-HPFS, Johnsen/HELGA, Iowa, ARIC, EPIC, PREDIMED) — re-pooling shared studies is laundered-E, so downgraded to F/shared and confidence heldlow. This is the finding the guard exists for; it would have read well as a confidence-raiser. - Same-quantity check on the two 90 g: AVOIDED. Aune’s 90 g (mostly fresh weight) vs NNR’s 90 g (dry weight) — flagged as a non-comparison from Aune’s own «only two publications … (dry weight)» sentence, not silently equated.
- No-optimum / no-U claims: correctly attributed. 90 g is a median not an optimum and benefit to 225 g/day, no plateau/harm arm within data are the wiki’s reading over Aune’s extracted studied-range and non-linearity results — tagged; the numbers themselves are extracted.
- Over-claim check: every effect cell carries RR + CI (+ studied range); NS cells (stroke, diabetes, nervous-system) marked; refined-grain read as no measured harm, not proven inert.
- Residual: F-not-E means this adds precision/shape, not an independent witness —
confidence: lowis unchanged, which is the honest outcome of the shared-cohort finding.
The third Aune plant-food MA lands — same lineage, NOT a third independent witness [2026-08-13]
Aune 2017 (F&V; ref 192-193 of that paper cite this whole-grain MA and the nut MA) completes the same-team plant-food trilogy (Aune et al., 2017). All three report an inverse all-cause association, but the increments differ, so the magnitudes are not rankable across foods:
| Parameter | Aune whole grain | Aune F&V | Same quantity? |
|---|---|---|---|
| All-cause RR | 0.83 per 90 g/day grain | 0.90 per 200 g/day F&V | NO — different increment AND different food; not comparable |
| Lineage | Imperial/NTNU, Aune-Norat-Riboli | same team, overlapping cohorts | shared |
- No
[E-independent]. The three MAs share method and a substantially overlapping primary-cohort base (NHS/HPFS, EPIC, ARIC, PREDIMED recur), so their agreement is same-lab type-F / shared lineage, exactly as the Reynolds denial above — team-count is not evidence-count. What F&V does add here is the recurring shape lesson: like whole grain, its guideline number (400 g/day / 5-a-day) marks the evidence density, with lowest risk out at the 800 g/day studied edge — a guideline threshold reading the data edge, not a curve feature -> Fruit and Vegetable Intake and Health.
Refinement — the DIfE/Boeing 12-food-group series (2026-08-28)
Across the five-outcome DIfE/Boeing dose-response series, whole grains are the single most consistently protective food in the whole matrix — protective across all five outcome families and the only food with two HIGH-grade cells: all-cause mortality RR 0.92 (0.89-0.95, per 30 g/d) and T2D incidence RR 0.87 (0.82-0.93, per 30 g/d), both nonlinear. (Schwingshackl et al., 2017) (Schwingshackl, Hoffmann, et al., 2017) By contrast refined grains are essentially null everywhere the series looks (mortality 0.99, T2D 1.01, CHD 1.01) — the whole-vs-refined contrast on this page is exactly what the matrix reproduces — and legumes are weak-to-null (mortality 0.96 NS, T2D 1.00, CHD 0.96 NS; one protective adiposity cell, RR 0.88, single study). (Bechthold et al., 2017) (Schlesinger et al., 2019) Full cross-outcome placement -> Food Groups and Health Outcomes - A Dose-Response Matrix.
The pulses G gap gets its dedicated SR+MA — cohort-null on events, benefit on risk factors [2026-08-28, Thorisdottir]
The G gap above (“the wiki cannot currently answer whether pulses help, harm or do nothing at realistic intakes”) now has the first source that is about legumes rather than mentioning them: Thorisdottir 2023, the legume SR+MA commissioned for the NNR2023 update. It pooled 47 studies — 31 prospective cohorts (2,081,432 participants, «generally low legume consumption») plus 14 crossover RCTs, one parallel RCT and one non-randomized trial — and separates the two evidence classes ESC ran together (surrogate vs hard outcome). (Thorisdottir et al., 2023)
The cohort arm is null on every hard endpoint (high-vs-low legume intake, random-effects RR):
| Outcome | RR (95% CI) | I2 | Reading |
|---|---|---|---|
| Total CVD | 0.95 (0.86, 1.06) | 41% | null |
| CVD mortality | 1.03 (0.89, 1.20) | 48% | null |
| Total CHD | 1.00 (0.95, 1.05) | 0% | null, tight |
| CHD incidence | 0.99 (0.94, 1.05) | 0% | null, tight |
| Total stroke | 0.98 (0.91, 1.05) | 16% | null |
| Stroke incidence | 0.99 (0.91, 1.09) | 34% | null |
| T2D incidence | 0.90 (0.77, 1.06) | 88% | null, very heterogeneous |
«No clear dose-response association was found for any of the outcomes», and the intake range is narrow by construction — Nordic mean legume intake is ~12 g/day, cohort exposure contrasts sit around that, so this is a null estimated across a low, compressed exposure range, not across the 120-150 g/day the RCTs used. The T2D estimate carries I2 = 88%: half the ten T2D cohorts reported a significant inverse association, one (Bazzano) a significant positive one, and the pooled 0.90 washes them out. (Thorisdottir et al., 2023)
The RCT arm — the evidence limb the cohort-only DIfE/Boeing series structurally lacks — shows benefit on risk factors (legume intervention vs control, weighted mean difference, ~120-150 g/day dry weight):
«The summary effect sizes (Fig. 5) showed significantly decreased TC (-0.22 mmol/L, 95% CI, -0.32, -0.13, I2 = 75%), LDL-cholesterol (-0.19 mmol/L, 95% CI, -0.27, -0.11, I2 = 52%), fasting glucose (-0.19 mmol/L, 95% CI, -0.33, -0.05, I2 = 83%), and HOMA-IR (-0.30, 95% CI, -0.60, -0.00, I2 = 96%) with legume interventions com pared with controls, but insignificant effects on HDL-C, TG, and insulin.» (Thorisdottir et al., 2023)
Type-B disaggregation — the LDL benefit is legume-general, the glycemic benefit is soynut-specific. Heterogeneity «decreased when separated by type of legumes… excluding the soynut trials removed nearly all heterogeneity.» With soynut trials excluded, the lipid effect survives (LDL-C -0.15 mmol/L, 95% CI -0.21, -0.09, I2 = 5%; TC -0.17, 95% CI -0.25, -0.09, I2 = 31%) while the glycemic effect collapses to null (fasting glucose -0.09, 95% CI -0.19, 0.01, I2 = 50%; HOMA-IR 0.01, 95% CI -0.01, 0.03, I2 = 0%). The glycemic movements were «only seen in RCTs from Iran on postmenopausal women with MetS consuming 30-35 g/day soynuts» — a single population and legume form. So “legumes lower blood sugar” is not supported for legumes-in-general; “legumes lower LDL” is. (Thorisdottir et al., 2023)
Type-F refinement of ESC’s bare sentence. ESC stated that a single daily portion of pulses lowers LDL-C by 0.2 mmol/L and «is associated with a lower risk of CHD» (the full verbatim is quoted in The pulses gap gets a first number above) — a surrogate limb with a number and a hard-outcome limb without one. Thorisdottir lets the wiki grade each:
- LDL limb — corroborated with an interval. ESC’s bare -0.2 mmol/L is matched by a pooled RCT MD of -0.19 mmol/L (95% CI -0.27, -0.11); the food-general form (soynut-excluded) is -0.15 (-0.21, -0.09). ESC’s point estimate now carries a confidence interval and a studied dose (~120-150 g/day, well above the “single portion” phrasing). This is F, not E — see the independence note below.
- CHD limb — NOT supported. ESC’s «associated with a lower risk of CHD» meets a dedicated pooled cohort estimate of RR 1.00 (0.95, 1.05), I2 = 0% — the tightest null in the table. The associational half of ESC’s sentence does not survive a purpose-built meta-analysis; the surrogate moved, the event did not.
The honest composite (type A) — a surrogate-vs-outcome gap, stated by the source itself. The overall WCRF-criteria grade was «limited – no conclusion», and the authors draw exactly the split the wiki’s surrogate discipline predicts:
«Legume consumption was not found to influence risk of CVD and T2D in healthy adult pop ulations with generally low legume consumption. However, protective effects on risk factors, seen in RCTs, lend some support for recommending legume consumption as part of diverse and healthy dietary patterns for prevention of CVD and T2D.» (Thorisdottir et al., 2023)
So the gap narrows, it does not close: legumes move LDL-C at RCT doses (robust, low-heterogeneity,
legume-general) and show no harm and no measured benefit on hard CVD/T2D events across the achievable
low-intake range — with the surrogate-to-outcome transmission unproven, [[Surrogate Outcomes]] the open
link. Blood pressure got «no conclusion» (data too limited). confidence: stays low.
Type-F, NOT type-E independence — shared team and shared cohort base. Thorisdottir is the NNR2023
Systematic Review Centre — the same group that produced the DIfE/Boeing-adjacent NNR SRs and the
Ramel white-meat SR on this vault — and its cohort pool overlaps the DIfE/Boeing series’ primary studies
(EPIC, ARIC, NHS/HPFS, PREDIMED cohorts recur). A shared team and a shared trial/cohort base defeat E
by construction: this is not a second independent witness raising confidence on the cohort nulls, it is
the same evidence appraised for a dedicated question. Its value is F — it adds the RCT risk-factor
arm the cohort-only matrix could not carry, and refines ESC’s undivided sentence — not E-corroboration
of the cohort nulls. No [E-independent] tag; the cohort-null agreement with DIfE/Boeing is shared-source,
not convergent-route.
Gaps that remain (G). No dose-response at any intake, so a minimum effective dose is undefined; the cohort range is compressed near the Nordic ~12 g/day mean, so the events null is weak at the intakes a Nordic eater would reach and uninformative about the 120-150 g/day RCT dose; blood pressure unconcluded; and the surrogate-to-hard-outcome link for the LDL benefit is assumed, not shown. Full cross-outcome placement -> Food Groups and Health Outcomes - A Dose-Response Matrix.
The pulses mortality cell gets its number — legume -> all-cause mortality, but no cause survives [2026-09-09, Zargarzadeh]
Thorisdottir covered legume -> CVD/T2D events (incidence) and RCT risk factors; the mortality endpoint was the open cell above. Zargarzadeh 2023 (Advances in Nutrition; SR + dose-response MA, 32 prospective cohorts / 31 publications, 1,141,793 participants, 93,373 all-cause deaths) fills it — and it is a dose-response MA, so it names the curve shape, not just a direction. (Zargarzadeh et al., 2023)
Exposure caveat first — this is NON-SOY legumes (type-B scope split from Thorisdottir, which included then separated soynut trials). Inclusion criterion 2:
«studies that re- ported total or subtypes of legume consumption, excluding soy foods, as the exposure or one of the exposure variables» (Zargarzadeh et al., 2023)
So Zargarzadeh’s «legumes» = beans / peas / lentils; the soynut LDL and glycemic movements Thorisdottir isolated sit outside this exposure entirely.
The mortality cells (highest vs lowest category, random-effects HR):
| Outcome | HR (95% CI) | n | I2 | Reading |
|---|---|---|---|---|
| All-cause | 0.94 (0.91, 0.98) | 27 | 64.6% | sig inverse |
| Stroke | 0.91 (0.84, 0.99) | 5 | 0% | sig but NOT robust (see below) |
| CVD | 0.99 (0.91, 1.09) | 11 | 56.6% | null |
| CHD | 0.93 (0.78, 1.09) | 5 | 65.9% | null |
| Cancer | 0.85 (0.72, 1.01) | 5 | 70.8% | null (marginal) |
Linear dose-response per 50 g/d — only all-cause survives: all-cause 0.94 (0.89, 0.99), n=19; CVD 1.01 (0.94, 1.08); CHD 0.90 (0.71, 1.13); stroke 0.90 (0.76, 1.06); cancer 0.82 (0.61, 1.10) — the last four all NS.
«The summary estimate showed that each 50 g/d increase in legume consumption was associated with a 6% reduction in the risk of all-cause mortality (HR: 0.94; 95% CI: 0.89, 0.99; Supplemental Figure 3).» (Zargarzadeh et al., 2023)
Dose-response shape — monotone over the modeled range, no knee, no plateau, no upper (harm) arm, no U. The nonlinear model found no departure from linearity for any outcome (all-cause P-nonlinearity 0.31; CVD 0.58; CHD 0.58; stroke 0.08; cancer 0.19), so over the studied increments the all-cause benefit is monotone per 50 g/d (portion = 100 g = 1 serving) with no knee located and no harm arm — there is no protective-plateau or U for the U-shape discipline to interrogate -> The U-Shaped Association Artifact. The 50 g/d increment is the reported unit; the paper does not state the numeric range bounds of the spline in-text (Figure 3 / supplement), so the shape claim is monotone over the modeled increment range, not a claim to a located optimum. (Zargarzadeh et al., 2023)
The caveat that guts most of the enthusiasm — the aggregate moves but no named cause does. Only all-cause is robustly significant. Stroke is significant but NOT robust:
«However, after the stepwise exclusion of each study in the sensitivity analysis, this association was not robust, and the results were influenced by the “Linxian Nutrition Intervention Trials” [36] and “Health Alcohol and Psychosocial Factors in Eastern Europe” [39].» (Zargarzadeh et al., 2023)
(drop either study and stroke -> HR 0.92, CI crossing 1). CVD, CHD and cancer are null. When an aggregate endpoint moves and its named components do not, the parsimonious reading is a power / residual-confounding artifact, not a broad causal effect — and the authors say exactly this:
«The re- ported discrepancies between the risk of incidence of all-cause mortality and death from CVD, CHD, and cancer are not totally evident. The protective association is most likely because of a greater number of studies in this area and, as a result, a greater number of participants and deaths.» (Zargarzadeh et al., 2023)
All-cause carries 93,373 deaths against 18,056 CVD / 12,890 cancer, so the all-cause significance may be power, not a distinct broad mechanism. The standard observational floor is stated in the authors’ own voice: «the risk of bias from confounding and exposure assessment will never be low» (Zargarzadeh et al., 2023). GRADE certainty: all-cause and stroke «moderate», CVD/CHD/cancer «low», none high, downgraded «chiefly» for residual confounding and inconsistency (Zargarzadeh et al., 2023).
Parameter table — Zargarzadeh vs Thorisdottir (op-weave 2a): mostly different quantity, one overlap
| Parameter | Zargarzadeh 2023 | Thorisdottir 2023 | Same quantity? |
|---|---|---|---|
| Primary endpoint | all-cause + cause-specific mortality | CVD/T2D events (incidence) + RCT risk factors | NO — mortality vs incidence/surrogate |
| All-cause mortality | 0.94 (0.91, 0.98) hi-lo; 0.94 (0.89, 0.99) /50 g | not estimated | NO — Thorisdottir has no all-cause arm |
| CVD mortality | 0.99 (0.91, 1.09) | 1.03 (0.89, 1.20) | YES — same endpoint; both null (not independent, see below) |
| Exposure | legumes excluding soy | legumes including soynut (then separated) | NO — soy scope differs |
| LDL / glycemic surrogate | not examined | RCT MD LDL -0.19 mmol/L; glucose soynut-specific | NO — surrogate, absent in Zargarzadeh |
So the genuinely NEW cells Zargarzadeh adds are all-cause, CHD, stroke and cancer mortality; the one OVERLAP (CVD mortality) agrees — both null, 0.99 vs 1.03 — but that agreement corroborates, it does not independently witness. This is additive-F (a new outcome family on the pulses cell), not E.
NOT type-E — the shared-Aune echo, killed on the author list first. Dagfinn Aune is a co-author of
Zargarzadeh AND already sits in this page’s sources: via Aune - Whole Grain Mortality 2016 and
Aune - Fruit Vegetable Mortality 2017. The cheapest independence test — diff the author lists — fails
at once: a Zargarzadeh legume-mortality dose-response that echoes the held Aune plant-food mortality
umbrellas is the same author and school, not a second route. (The held Aune sources are whole-grain
and F&V, not legumes, so there is no same-quantity Aune legume-mortality figure being duplicated — the
echo risk is authorship + method, not a re-pooled estimate.) Zargarzadeh is also a cohort-pooling MA on a
legume-cohort base overlapping Thorisdottir’s. Shared author + shared cohorts + shared method =
F/shared, not E: no [E-independent], and the CVD-mortality agreement with Thorisdottir plus the
all-cause agreement with the Aune lineage are shared-source, not convergent-route. Team/paper count is
not evidence count.
G-gap status change + confidence. The pulses cell moves from «cohort-null on events, LDL benefit at
RCT doses, no mortality data» to «non-soy legumes -> ~6% lower all-cause mortality per 50 g/d (moderate
certainty), monotone with no knee, but no robust signal on any specific cause of death». This is the
strongest pulse -> hard-outcome signal the page holds, yet confidence: stays low: it is
observational and measurement-error-attenuated, the all-cause signal may be power/confounding rather than a
broad effect (author-stated), stroke is non-robust, and the source is not independent of the held
Aune/Thorisdottir lineage. What remains open (G): no minimum effective dose (no knee), and the mechanism
by which non-soy legumes would lower all-cause death without moving a named cause is unresolved.
Full cross-outcome placement -> Food Groups and Health Outcomes - A Dose-Response Matrix.
Self-critique of the Zargarzadeh addition [run 2026-09-09, before commit]
- Laundered-independence check: FIRED, and
[E-independent]was NOT claimed. The attractive claim was a large independent legume-mortality MA confirms the plant-food mortality signal. Dagfinn Aune is a co-author and already in the page’ssources:(whole-grain + F&V), and the cohort base overlaps Thorisdottir — so this is F/shared on both authorship and data. Confidence heldlow. This is the finding the guard exists for; it would have read well as a confidence-raiser. - Overclaim check on the all-cause signal: caught in the body. All-cause is significant while every named cause is null or non-robust; rather than report «legumes cut mortality», the section states the power/residual-confounding reading the authors themselves give, and keeps the certainty at the source’s own GRADE (moderate all-cause, low the rest).
- Same-quantity checks: one YES, four NO. The parameter table matches CVD mortality across the two MAs (both null) and marks the endpoint/exposure/surrogate rows as different quantities — no cross-MA magnitude was ranked that wasn’t the same estimand.
- U-shape / dose-response: declined to assert a knee. No nonlinearity for any outcome; stated as monotone over the modeled increment range with no located optimum, and the numeric range bounds were NOT invented (not in the in-text; Figure 3 / supplement).
- QUALIFIER-LEFT-OUT on the 50 g/d quote: defended.
cite.pyflagged the following sentence (the nonlinearity result) as omitted; it is stated explicitly in the dose-response-shape paragraph, so the truncation does not hide a reversing qualifier. - Residual: F-not-E means this adds a new outcome family and precision, not an independent witness —
confidence: lowis unchanged, which is the honest outcome of the shared-author/shared-cohort finding.